Oncolys BioPharma Inc. - ROE
4588.T
Price:
$6350
Market Cap:
$185.95B
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infe...[Read more]
Industry
Biotechnology
IPO Date
2013-12-06
Stock Exchange
JPX
Ticker
4588.T
PE Ratio
[-119.39]
ROE
[-47.76%]
Current Ratio
[3.91]
Dividend Yield
[0%]
Enterprise Value
[183.81B]
Dividend History
The ROE as of October 2026 (TTM) for Oncolys BioPharma Inc. (4588.T) is -47.76%
According to Oncolys BioPharma Inc.’s latest financial reports and current stock price. The company's current ROE is -47.76%. This represents a change of 279.12% compared to the average of -12.60% of the last 4 quarters.
Oncolys BioPharma Inc. (4588.T) Historical ROE (quarterly & annually)
How has 4588.T ROE performed in the past?
The mean historical ROE of Oncolys BioPharma Inc. over the last ten years is -58.86%. The current -47.76% ROE has changed -18.86% with respect to the historical average. Over the past ten years (40 quarters), 4588.T's ROE was at its highest in in the June 2019 quarter at 2.18%. The ROE was at its lowest in in the December 2023 quarter at -45.16%.
Average
-58.86%
Median
-48.20%
Minimum
-131.50%
Maximum
-26.41%
Oncolys BioPharma Inc. (4588.T) ROE by Quarter and Year
Discovering the peaks and valleys of Oncolys BioPharma Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 295.93%
Maximum Annual ROE = -26.41%
Minimum Annual Increase = -57.02%
Minimum Annual ROE = -131.50%
| Year | ROE | Change |
|---|---|---|
| 2025 | -51.45% | -15.95% |
| 2024 | -61.22% | -53.45% |
| 2023 | -131.50% | 147.14% |
| 2022 | -53.21% | 18.38% |
| 2021 | -44.95% | -57.02% |
| 2020 | -104.58% | 295.93% |
| 2019 | -26.41% | -37.89% |
| 2018 | -42.53% | 14.32% |
| 2017 | -37.20% | 4.54% |
| 2016 | -35.59% | 45.34% |
Oncolys BioPharma Inc. (4588.T) Average ROE
How has 4588.T ROE performed in the past?
The current ROE of Oncolys BioPharma Inc. (4588.T) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-81.39%
5-year avg
-68.47%
10-year avg
-58.86%
Oncolys BioPharma Inc. (4588.T) ROE vs. Peers
How is 4588.T’s ROE compared to its peers?
Oncolys BioPharma Inc.’s ROE is greater than Delta-Fly Pharma, Inc. (-1678.17%), greater than Noile-Immune Biotech Inc. (-19.57%), greater than OncoTherapy Science, Inc. (-42.79%), greater than CanBas Co., Ltd. (-60.26%), greater than BrightPath Biotherapeutics Co., Ltd. (-93.35%), greater than Chordia Therapeutics Inc. (-61.16%),
| Company | ROE | Market cap |
|---|---|---|
| -1678.17% | $1.49B | |
| -19.57% | $4.55B | |
| -42.79% | $7.97B | |
| -60.26% | $15.37B | |
| -93.35% | $3.78B | |
| -61.16% | $4.51B |
Build a custom stock screener for Oncolys BioPharma Inc. (4588.T) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncolys BioPharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Oncolys BioPharma Inc. (4588.T) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Oncolys BioPharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Oncolys BioPharma Inc.'s ROE?
How is the ROE calculated for Oncolys BioPharma Inc. (4588.T)?
What is the highest ROE for Oncolys BioPharma Inc. (4588.T)?
What is the 3-year average ROE for Oncolys BioPharma Inc. (4588.T)?
What is the 5-year average ROE for Oncolys BioPharma Inc. (4588.T)?
How does the current ROE for Oncolys BioPharma Inc. (4588.T) compare to its historical average?